Women With Stomach Cancer Likely to Survive Longer Than Men

Women with stomach cancer live longer than men suffering from the condition, a study has found.

Published29 May 2019, 10:11 AM IST
Cancer
2 min read

Researchers have found that female patients with oesophagus and stomach cancer are likely to survive longer than male patients, but experience more nausea, vomiting and diarrhoea during therapy.

The findings of a latest UK study could potentially help in managing patients and also highlight who are more at risk against specific side effects.

According to study lead author Avani Athauda from Royal Marsden Hospital in Britain, “We tend to use a standard treatment approach for managing oesophageal and stomach cancers.”

What this research suggests is that there are significant differences between male and female patients not only in how they react to chemotherapy but also how long they survive following treatment for their cancer.

"For female patients, it may be worthwhile providing additional awareness and counselling for gastrointestinal side effects when prescribing chemotherapy," Athauda said.

For the study, the researchers conducted an analysis on data taken from four previously published large randomised trials conducted primarily in the UK.

Patients in the trials had been allocated to receive chemotherapy before undergoing surgery to remove the tumours.

In the analysis of over 3,000 patients (2,668 male patients and 597 female), the researchers found female patients were significantly more likely to experience nausea (10 per cent versus 5 per cent), vomiting (10 per cent versus 4 per cent) and diarrhoea (9 per cent versus 4 per cent).

Female patients were also significantly more likely to live longer than male ones following treatment for their cancer, said the study.

David Cunningham, Professor at the University of London, said,

This is a significant finding based on a large scale data set, and furthers our understanding about two types of cancer that affect almost 16,000 people each year in the UK alone.

The study is scheduled to be presented at American Society of Clinical Oncology's (ASCO)annual meeting in Chicago.

(This story was auto-published from a syndicated feed. Only the title and the image have been edited by FIT)

(This story was published from a syndicated feed. Only the headline and picture has been edited by FIT)

Subscribe to FIT on Telegram

Never Miss Out

Stay tuned with our weekly recap of what’s hot & cool by The Quint.

Join over 120,000 subscribers!